Cargando…

Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial

Objective. The aim of this analysis is to examine the longitudinal impact of symptoms of depression/anxiety on treatment response, long-term disease activity and physical disability in RA. Methods. Secondary analysis of clinical trial data was performed. Data were collected at baseline and at 6-mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Matcham, Faith, Norton, Sam, Scott, David L., Steer, Sophia, Hotopf, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710801/
https://www.ncbi.nlm.nih.gov/pubmed/26350486
http://dx.doi.org/10.1093/rheumatology/kev306
_version_ 1782409859885432832
author Matcham, Faith
Norton, Sam
Scott, David L.
Steer, Sophia
Hotopf, Matthew
author_facet Matcham, Faith
Norton, Sam
Scott, David L.
Steer, Sophia
Hotopf, Matthew
author_sort Matcham, Faith
collection PubMed
description Objective. The aim of this analysis is to examine the longitudinal impact of symptoms of depression/anxiety on treatment response, long-term disease activity and physical disability in RA. Methods. Secondary analysis of clinical trial data was performed. Data were collected at baseline and at 6-monthly intervals for 2 years. The EuroQoL (EQ-5D(TM)) indicated depression/anxiety symptom severity. Our primary outcomes of interest were (i) DAS-28 and (ii) physical disability measured via the HAQ. Secondary outcomes were: tender and swollen joint counts, patient global assessment, ESR and odds of reaching clinical remission. Multilevel models were used to assess the impact of baseline and persistent depression/anxiety on outcomes over 2 years. Results. Data from 379 patients were included. After adjusting for covariates, baseline depression/anxiety symptoms were associated with increased DAS-28 outcomes and increased tender joint counts. Persistent depression/anxiety symptoms were associated with increased DAS-28 scores, HAQ scores, tender joint counts and patient global assessment of disease activity, and reduced odds of reaching clinical remission. Patients with symptoms of depression/anxiety at baseline also showed a 50% reduction in prednisolone treatment effect, in comparison with patients with no symptoms of depression/anxiety at baseline. Conclusion. Baseline and persistent symptoms of depression/anxiety are associated with poorer health outcomes over time, as well as reduced treatment response. Mental health should be routinely measured both in clinical practice and in research, and managed alongside rheumatological disease to optimize health outcomes. Further research is required to examine whether treatment of mental disorders can improve rheumatological outcomes.
format Online
Article
Text
id pubmed-4710801
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47108012016-01-13 Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial Matcham, Faith Norton, Sam Scott, David L. Steer, Sophia Hotopf, Matthew Rheumatology (Oxford) Clinical Science Objective. The aim of this analysis is to examine the longitudinal impact of symptoms of depression/anxiety on treatment response, long-term disease activity and physical disability in RA. Methods. Secondary analysis of clinical trial data was performed. Data were collected at baseline and at 6-monthly intervals for 2 years. The EuroQoL (EQ-5D(TM)) indicated depression/anxiety symptom severity. Our primary outcomes of interest were (i) DAS-28 and (ii) physical disability measured via the HAQ. Secondary outcomes were: tender and swollen joint counts, patient global assessment, ESR and odds of reaching clinical remission. Multilevel models were used to assess the impact of baseline and persistent depression/anxiety on outcomes over 2 years. Results. Data from 379 patients were included. After adjusting for covariates, baseline depression/anxiety symptoms were associated with increased DAS-28 outcomes and increased tender joint counts. Persistent depression/anxiety symptoms were associated with increased DAS-28 scores, HAQ scores, tender joint counts and patient global assessment of disease activity, and reduced odds of reaching clinical remission. Patients with symptoms of depression/anxiety at baseline also showed a 50% reduction in prednisolone treatment effect, in comparison with patients with no symptoms of depression/anxiety at baseline. Conclusion. Baseline and persistent symptoms of depression/anxiety are associated with poorer health outcomes over time, as well as reduced treatment response. Mental health should be routinely measured both in clinical practice and in research, and managed alongside rheumatological disease to optimize health outcomes. Further research is required to examine whether treatment of mental disorders can improve rheumatological outcomes. Oxford University Press 2016-02 2015-09-08 /pmc/articles/PMC4710801/ /pubmed/26350486 http://dx.doi.org/10.1093/rheumatology/kev306 Text en © The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Matcham, Faith
Norton, Sam
Scott, David L.
Steer, Sophia
Hotopf, Matthew
Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
title Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
title_full Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
title_fullStr Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
title_full_unstemmed Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
title_short Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
title_sort symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710801/
https://www.ncbi.nlm.nih.gov/pubmed/26350486
http://dx.doi.org/10.1093/rheumatology/kev306
work_keys_str_mv AT matchamfaith symptomsofdepressionandanxietypredicttreatmentresponseandlongtermphysicalhealthoutcomesinrheumatoidarthritissecondaryanalysisofarandomizedcontrolledtrial
AT nortonsam symptomsofdepressionandanxietypredicttreatmentresponseandlongtermphysicalhealthoutcomesinrheumatoidarthritissecondaryanalysisofarandomizedcontrolledtrial
AT scottdavidl symptomsofdepressionandanxietypredicttreatmentresponseandlongtermphysicalhealthoutcomesinrheumatoidarthritissecondaryanalysisofarandomizedcontrolledtrial
AT steersophia symptomsofdepressionandanxietypredicttreatmentresponseandlongtermphysicalhealthoutcomesinrheumatoidarthritissecondaryanalysisofarandomizedcontrolledtrial
AT hotopfmatthew symptomsofdepressionandanxietypredicttreatmentresponseandlongtermphysicalhealthoutcomesinrheumatoidarthritissecondaryanalysisofarandomizedcontrolledtrial